Comparative Pharmacology
Head-to-head clinical analysis: ELEPSIA XR versus KEPPRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELEPSIA XR versus KEPPRA XR.
ELEPSIA XR vs KEPPRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
None Documented
None Documented
Terminal elimination half-life is 14-17 hours; requires dose adjustment in renal impairment.
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Primarily renal (70% unchanged, 20% as inactive metabolites); minor fecal (10%).
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Category C
Category C
Antiepileptic
Antiepileptic